These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875 [TBL] [Abstract][Full Text] [Related]
7. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699 [TBL] [Abstract][Full Text] [Related]
8. Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Murciano-Goroff YR; Schram AM; Rosen EY; Won H; Gong Y; Noronha AM; Janjigian YY; Stadler ZK; Chang JC; Yang SR; Mandelker D; Offit K; Berger MF; Donoghue MTA; Bandlamudi C; Drilon A Nat Commun; 2022 Nov; 13(1):7182. PubMed ID: 36418296 [TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 reversion mutations in a pan-cancer cohort. Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241 [TBL] [Abstract][Full Text] [Related]
10. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
11. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233 [TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561 [TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282 [TBL] [Abstract][Full Text] [Related]
14. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib. Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343 [TBL] [Abstract][Full Text] [Related]
15. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669 [TBL] [Abstract][Full Text] [Related]
16. BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. Pepe F; Pisapia P; Russo G; Nacchio M; Pallante P; Vigliar E; De Angelis C; Insabato L; Bellevicine C; De Placido S; Troncone G; Malapelle U Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946865 [TBL] [Abstract][Full Text] [Related]
17. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925 [TBL] [Abstract][Full Text] [Related]
18. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
19. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. Lheureux S; Prokopec SD; Oldfield LE; Gonzalez-Ochoa E; Bruce JP; Wong D; Danesh A; Torti D; Torchia J; Fortuna A; Singh S; Irving M; Marsh K; Lam B; Speers V; Yosifova A; Oaknin A; Madariaga A; Dhani NC; Bowering V; Oza AM; Pugh TJ Clin Cancer Res; 2023 Sep; 29(18):3706-3716. PubMed ID: 37327320 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients. Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878 [No Abstract] [Full Text] [Related] [Next] [New Search]